S
troke remains the number one cause of disability among Americans each year. Besides thrombolytic treatments, which have a very narrow time window and limited availability, 1 there are currently no other therapeutic approaches. Promising novel therapeutic strategies, such as cell transplantation, 2 are moving toward clinical trials, but there is a significant lack of clinically applicable methods to guide and monitor such therapies. Molecular imaging, a recently emerged field that seeks to quantitatively measure biological processes at the cellular and molecular level in vivo, 3 can be a valuable tool for these applications. Major areas of molecular imaging in stroke research include metabolic imaging without contrast agents, 4 labeling methods for tracking stem cells and macrophages migrating into ischemic brain regions, 5 probes that can reflect the metabolic status, 6, 7 and probes that binding specifically to stroke markers. 8 One potentially important repair mechanism after stroke is angiogenesis, 9,10 the formation of new blood vessels. Increased expression of vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) plays important roles during neurovascular repair after stroke. 11 Human neural stem cells overexpressing VEGF have been shown to provide neuroprotection and enhance angiogenesis. 12 Because ischemia and cell transplantation can enhance VEGFR expression, 13, 14 in vivo imaging of VEGFR could be a valuable indicator for the repair mechanisms occurring after stroke.
Positron emission tomography (PET) has been widely used in the clinic for diagnosis and treatment monitoring. 15 We recently developed a tracer, 64 Cu-DOTA-VEGF 121 (DOTA denotes 1,4,7,10-Tetraazacyclododecane-N,NЈ,NЉ,Nٞ-tetraacetic acid), which can enable PET imaging of VEGFR expression in various disease models. 16, 17 Herein, we demonstrate for the first time to our knowledge the in vivo imaging of VEGFR expression after acute experimental stroke.
Materials and Methods

Distal Middle Cerebral Artery Occlusion Surgery
All experimental protocols performed on animals were approved by the Stanford University Administrative Panel on Laboratory Animal Care. Focal cerebral ischemia (distal middle cerebral artery occlusion [dMCAo] model) was generated as described previously. 18 Sham-operated animals (controls) underwent the same surgery without occlusion of the blood vessels. Daily intraperitoneal injections with 5-bromo-2Ј-deoxyuridine (BrdU) were administered in 3 mice for 7 days after dMCAo.
I-VEGF 165 (GE Healthcare) as the radio-ligand. The best-fit IC 50 values were calculated by fitting the data by nonlinear regression using GraphPad Prism Software. Experiments were performed with triplicate samples.
MRI Protocol
The MR frame consisted of a nonmagnetic stereotactic wrist coil with a cylindrical surface coil (5-cm internal diameter) positioned directly over the rat head. MR imaging was performed in a 3-T whole-body MR scanner (GE Healthcare). Rats were anesthetized during imaging using 1% to 2% inhaled isoflurane. The brain of each rat was imaged weekly with T2-weighted fast-spin echo sequence (receiver bandwidthϭ16 kHz; repetition timeϭ5000 ms; echo timeϭ86 ms; echo train lengthϭ8; field of viewϭ4ϫ4 cm; matrixϭ256ϫ256; 16 slices; slice thicknessϭ1 mm; number of signals averagedϭ3; total imaging timeϭ8 min). The MR images were analyzed using Image J software (http://rsb.info.nih.gov/ij/). The stroke area in each MR image was traced and measured to calculate the stroke volume.
MicroPET Studies
Weekly PET scans of the rats were performed on a microPET R4 rodent model scanner (Siemens Medical Solutions). 16,21 64 CuCl 2 (10 mCi) was diluted in 300 L of 0.1 mol/L sodium acetate buffer (pHϭ6.5) and added to 100 g DOTA-VEGF 121 or DOTA-VEGF mutant . 16, 22 The reaction mixture was incubated for 1 hour at 40°C with constant shaking. 64 Cu-DOTA-VEGF 121 and 64 Cu-DOTA-VEGF DEE were then purified by size exclusion chromatography using phosphate-buffered saline as the mobile phase. The radiochemical purity was Ͼ98%.
Each rat was intravenously injected with Ϸ1 mCi tracer ( 18 F-FDG, 64 Cu-DOTA-VEGF 121 , or 64 Cu-DOTA-VEGF mutant ). For 18 F-FDG, the rats were scanned at 1 hour after injection. For 64 Cu-DOTA-VEGF 121 or 64 Cu-DOTA-VEGF mutant , the rats were scanned at multiple time points in pilot studies (1, 2, and 4 hours after injection); 2 hours after injection was chosen because of the best contrast observed. For each PET scan, 3-dimensional regions of interest were drawn over the stroke area on decay-corrected images. The average radioactivity concentration was obtained from the mean pixel values within the region of interest volume, which were converted to counts per milliliter per minute by use of a predetermined conversion factor. Given a tissue density of 1 g/mL, the counts per milliliter per minute were converted to counts per gram per minute, and the values were divided by the injected dose to obtain the imaging region of interest derived percentage injected dose per gram (%ID/g).
Autoradiography
Detailed procedure of autoradiography was reported earlier. 23 The perfused and acetone fixed rat brain slices (with or without the stroke 
Histology
Stroke rats at different days after surgery were transcardially perfused with saline, followed by 3% paraformaldehyde. The brains were removed and postfixed for 24 hours in 3% paraformaldehyde, followed by cryo-preservation in 3% paraformaldehyde/20% sucrose for 48 hours. Subsequently, the brains were embedded in optimal cutting temperature compound (OCT) and cut into 20-m sections.
All primary antibodies were diluted in phosphate-buffered saline/ 0.3% Triton containing 1% bovine serum albumin (BSA). The following antibodies were used: rabbit anti-VEGFR-1 (Laboratory Vision Corp; 1:50), rabbit anti-VEGFR-2 (Laboratory Vision Corp; 1:50), mouse anti-lectin (Vector Labs; 1:250), mouse anti-BrdU (Vector Labs; 1:250), mouse anti-GFAP (Advanced ImmunoChemicals; 1:800), mouse anti-NeuN (R&D Systems; 1:500), FITC donkey anti-rabbit (Jackson ImmunoResearch; 1:500), and Cy3 goat antimouse (Jackson ImmunoResearch; 1:500). For double staining of lectin and BrdU, the lectin stain was performed and the tissue postfixed in 3% paraformaldehyde for 10 minutes at 4°C. After thorough washes, the sections were treated with 3 mol/L HCl for 30 minutes at 37°C. After blocking and washing, the sections were incubated with mouse anti-BrdU, followed by a secondary antibody. 4Ј,6-Diamidino-2-phenylindole was used to label the nuclei (SigmaAldrich; 1:1000). Sections were analyzed on a confocal laser scanning microscope (Zeiss) with split panel and z-axis analysis to confirm marker colocalization. VEGFR-2 expression was quantified in 3 high-power fields in the stroke border zone at 2, 10, and 17 days after stroke. The percent area in each high power field covered by VEGFR-2 immunoreactivity was measured using Image J.
Statistical Analysis
Quantitative data were expressed as meanϮSD. Means were compared using 1-way analysis of variance and Student t test. PϽ0.05 was considered statistically significant.
Results
Stroke Morphology and Size
A group of 4 dMCAo rats underwent weekly T2-weighted MRI, 18 F-FDG, and 64 Cu-DOTA-VEGF 121 scans. A successful stroke surgery and focal cortical stroke in the left hemisphere was confirmed for all animals on T2-weighted MRI ( Figure  1A ). The stroke volume based on MRI was 244.7Ϯ33.5, 153.6Ϯ41.9, and 152.6Ϯ42.1 mm 3 at days 1, 8, and 15, respectively ( Figure 1B; nϭ4) . Typically, the stroke size is overestimated on T2-weighted MRI early after surgery because of edema, which appears hyperintense in the images. Hence, the lesion size significantly decreased from day 1 to day 8 after surgery but remained stable thereafter, with the true stroke size being Ϸ150 mm 3 ( Figure 1B ). Hematoxylin and eosin staining confirmed the stroke presence ( Figure 1C ). Sham-operated rats were also prepared and no stroke was observed in their brains based on MRI.
F-FDG PET
Normal brain tissue has prominent uptake of 18 F-FDG because of the constant need for glucose in the brain. 24 A "cold spot" was seen in the 18 F-FDG PET of dMCAo rat brain, which corresponds to the stroke area delineated by MRI ( Figure 1D ). The contralateral brain uptake of 18 F-FDG 
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remained constant at Ϸ1.0 to 1.1%ID/g, whereas that of the stroke area was significantly lower at all time points examined ( Figure 1E ; PϽ0.05; nϭ4). The uptake in the stroke area was Ϸ0.5%ID/g at days 1, 15, and 22. At day 8, the stroke area appeared to be smaller and the uptake was higher (0.76Ϯ0.11%ID/g). Such phenomenon is likely attributable to inflammation in the stroke area because 18 F-FDG has been well-established to be taken up by inflamed tissue (which does not significantly affect the MR images). 25, 26 64 Cu-DOTA-VEGF 121 PET
The day after the MRI and 18 F-FDG scans, the rats were subjected to 64 Cu-DOTA-VEGF 121 PET. Uptake in the stroke area could be clearly seen as early as day 2 (0.24Ϯ 0.02%ID/g; nϭ4; Figure 2A,B) . The uptake in the stroke area peaked at day 9 (0.46Ϯ0.11%ID/g) and remained elevated at day 16 (0.29Ϯ0.10%ID/g). The uptake in the contralateral brain was low at all time points (Ͻ0.10%ID/g). At day 23, the uptake in the stroke area was no longer statistically significantly different from the background (0.06Ϯ0.04%ID/g vs 0.03Ϯ 0.02%ID/g, respectively; nϭ4). The stroke-to-normal tissue uptake ratio was 12.5Ϯ1.6, 9.0Ϯ1.8, 3.2Ϯ1.6, and 2.1Ϯ1.9 at days 2, 9, 16, and 23, respectively (nϭ4; Figure 2C ). The uptake of 64 Cu-DOTA-VEGF 121 in the surgical wound was prominent in most of the images because angiogenesis is also a key process during wound healing.
To validate VEGFR expression in the stroke border zone, 125 I-VEGF 165 autoradiography was performed on brain slices at day 2 and day 9 after surgery because good stroke-tonormal tissue ratios were observed at these time points. Clearly, VEGFR expression was seen at the proximity of the stroke area but not in the contralateral brain or the normal brain tissue ( Figure 2D ). The site of VEGFR overexpression correlates to the area with 64 Cu-DOTA-VEGF 121 uptake in the PET scans.
Cu-DOTA-VEGF mutant PET and Sham-Operated Rats
Several control experiments were performed to confirm VEGFR specificity of 64 Cu-DOTA-VEGF 121 uptake. The VEGF mutant does not bind to VEGFR-2 with an IC 50 value of Ͼ10 mol/L (2.8 nmol/L for VEGF 121 ; Figure 3A ). For VEGFR-1, the IC 50 values of VEGF 121 and VEGF mutant were 5.4 nmol/L and 11.3 nmol/L, respectively ( Figure 3B ). A group of 3 dMCAo rats ( Figure 3C ) were prepared and subjected to 64 Cu-DOTA-VEGF mutant scans at day 10 after surgery (when the uptake of 64 Cu-DOTA-VEGF 121 was the highest in the stroke border zone). The uptake of 64 Cu-DOTA-VEGF mutant in the stroke border zone was significantly lower than that of 64 Cu-DOTA-VEGF 121 (0.20Ϯ0.08%ID/g vs 0.46Ϯ0.11%ID/g; PϽ0.05; Figure 3D ).
Three sham-operated rats were prepared and both MRI and 18 F-FDG PET confirmed the lack of stroke in the rat brain ( Figure 4A ). Subsequent 64 Cu-DOTA-VEGF 121 scans revealed that the tracer uptake was in the wound, but not in the brain (Ͻ0.10%ID/g at days 9 and 16; nϭ3; Figure 4B ). The wound uptake was the highest at day 2, and was significantly lower at day 9 and day 16. Taken together, these 2 sets of control experiments confirmed that the 64 Cu-DOTA-VEGF 121 uptake in the stroke border zone was VEGFR-specific ( Figure 4C ).
Histology
Stroke morphology as seen on hematoxylin and eosin-stained sections correlated well with that observed in MRI and PET ( Figure 1C ). VEGFR-2 was expressed in the stroke border zone as early as 2 days after surgery with predominantly cellular expression ( Figure 5A ). At 10 days after surgery, a mixed cellular and vascular expression pattern was noted ( Figure 5B,D) , which decreased significantly at day 17 ( Figure 5C ). Phenotypic characterization showed colocalization of VEGFR-2 with astrocytes (GFAP; Figure 5E ), neu- rons (NeuN; Figure 5F ), and blood vessels (Lectin; Figure  5G ) at day 10 after stroke. Quantification of VEGFR-2 expression in the stroke border zone confirmed the PET findings with a peak expression at day 10 ( Figure 5H ). The overall expression between day 2 and day 10 was not significantly different, but there was markedly less vascular expression at day 2 after stroke. VEGFR-2 expression in the contralateral brain and normal brain tissue was minimal and VEGFR-1 staining of the dMCAo rat brain slices was also weak at all time points (data not shown). BrdU staining at day 10 demonstrated numerous BrdU-positive cells in the stroke border zone (Figure 6A,B) . Colocalization of lectin and BrdU further substantiated the presence of poststroke angiogenesis ( Figure 6B,C) .
Discussion
No treatment currently exists to restore the lost neurological function after stroke. Increased vascularization in the stroke border zone within a few days after stroke is associated with neurological recovery. 27 Stem cells, 28 erythropoietin, 29 chemokines, 30 and gene therapy, 31 among others, have been shown to induce angiogenesis after stroke. Noninvasive molecular imaging of poststroke angiogenesis, such as the one demonstrated here, could be extremely valuable not only as a prognostic factor but also as a measurement of success to help guide proangiogenic therapies. Different scenarios can be envisioned. To date we do not know the right timing or the ideal place for cell or drug delivery in future clinical trials with stroke patients. It is conceivable that molecular imaging techniques will not only help us monitor the therapy effects but also help us defining patient specific treatment strategies. Moreover, it is also possible that early molecular and biological events (assessable by molecular imaging) might be predictors of clinical outcome.
Upregulation of VEGFR was already found at 2 days poststroke, indicating that signals to induce angiogenesis appear very rapidly after stroke. The uptake of 64 Cu-DOTA-VEGF 121 in the stroke border zone peaked at Ϸ10 days after surgery (significantly higher than the baseline uptake at days 2, 9 and 16, but not at day 23), confirmed by both histology and autoradiography, which showed that VEGFR-2 expression peaked at Ϸ10 days after stroke (Figures 2 and 5 ). Previous studies have demonstrated peak VEGF expression between 12 and 24 hours, preceding VEGFR-2 expression. 32 Whereas VEGFR-1 mRNA level returned to baseline after 7 days, the VEGFR-2 mRNA level persisted for 7 days. 32 64 Cu-DOTA-VEGF 121 binds to both receptors; 16 therefore, it cannot differentiate between VEGFR-1 and VEGFR-2. However, the significantly lower uptake of 64 Cu-DOTA-VEGF mutant , which does not bind to VEGFR-2 but binds to VEGFR-1 with lower affinity than 64 Cu-DOTA-VEGF 121 ( Figure 3A ,B), at day 10 in the stroke border zone suggests that VEGFR-2 may play a more dominant role over VEGFR-1 in poststroke angiogenesis. In agreement with previous studies, VEGFR-2 expression was concentrated around the stroke border zone 32 and was found to colocalize with the blood vessels, astrocytes, and neurons ( Figure 5 ). 33, 34 BrdU staining further confirmed the active formation of new blood vessels ( Figure 6 ).
Because there is a blood-brain barrier instability after stroke, partially influenced by VEGF, 34 it is possible that our imaging not only represents endoluminal but also represents some cellular expression of VEGFR. Recently, VEGFR upregulation in the ventral premotor hand representation and the M1 hind limb representation in squirrel monkeys 3 days after stroke were reported. 35 This underscores the potential importance of VEGF/VEGFR pathway not only in acute stroke but also in poststroke plasticity and perhaps long-term rehabilitation.
Imaging VEGF and VEGFR expression are both important for diagnosis and monitoring of angiogenesis-related treatment efficacy. Although increased expression of growth factors and cytokines occurs in many stroke models, many of the signaling pathways that are responsible for revascularization have only been subjectively proposed based on ex vivo/in vitro studies. Much research will be needed to develop blood-brain barrier-penetrating tracers for imaging VEGF expression in the (stroke) brain. We envision that examining the stroke brain in the same animals or patients with both VEGF-and VEGFR-targeted tracers may give important insights about the expression kinetics of VEGF and VEGFR and may shed new light on the disease/recovery mechanisms based on VEGF/VEGFR signaling. Generation of VEGFR-1-specific or VEGFR-2-specific VEGF mutant without any affinity to the other receptor may also help us better understand poststroke angiogenesis in future studies. Besides VEGF/VEGFR imaging, other angiogenesis-related targets such as integrin ␣ v ␤ 3 should also be studied in the future. 36 In this study, the wound in the rat skin is close to the stroke area. In pilot studies, we also created a group of stroke rats using a suture model in which the wound is not directly adjacent to the stroke area. However, we found that the stroke size varies to a great extent between animals, which led to less reproducible results in MRI, 18 F-FDG, and 64 Cu-DOTA-VEGF 121 PET scans. Therefore, we chose the dMCAo model in which the stroke size in each rat is quite consistent. Recent development of hybrid PET/MR scanners may facilitate the coregistration of the MR and PET images in future studies for differentiation between stroke and normal brain tissue. Nonetheless, control experiments in sham-operated rats, the use of a VEGF mutant , autoradiography, and histology all clearly demonstrated that the uptake in the stroke border zone is attributable to VEGFR overexpression in poststroke angiogenesis.
Summary
Multimodality imaging was used to assess the temporal profile of the lesion size, metabolic activity, and angiogenesis in the same animals after stroke. For the first time to our knowledge, we successfully evaluated the time-course of VEGFR expression noninvasively by PET in a rat stroke model. The ability to visualize VEGFR expression level in vivo could provide new opportunities to document angiogenesis after stroke, which may have significant clinical implications in guiding future therapies aimed at improving angiogenesis. Future studies of imaging VEGFR expression before, during, and after new stroke therapies are warranted.
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